Engine Biosciences combines machine learning-enabled network biology and high-throughput combinatorial genetics to discover precision oncology targets, biomarkers, and drug candidates. Its proprietary platforms, NetMAPPR and CombiGEM, integrate proprietary functional genomics, clinical data and AI-enhanced literature mining to map disease networks and validate findings. Engine has identified over thirty previously unidentified precision medicine opportunities and advanced multiple internal programs, including ENB-812, which originated from Engine’s discovery of PKMYT1 as a synthetic lethal target. The company reports biomarkers that can sensitize tumors up to 100-fold to specific investigational drugs and holds an extensive patent portfolio. With teams in Singapore and Silicon Valley, Engine is advancing its pipeline toward the clinic through internal development, collaborations, and partnerships. The new financing is intended to further progress biomarker and target discoveries into clinical translation. Engine Biosciences develops a platform that integrates machine learning, high-throughput biological experimentation, combinatorial genetics, and chemistry to uncover critical gene interactions for drug discovery. Its core technologies are NetMAPPR, a searchable biology platform for predicting gene combinations and targets, and CombiGEM, a combinatorial CRISPR system for experimentally testing hundreds of thousands of gene interactions. Engine uses iterative predict-test-learn cycles to prioritize high-ranking genes and translate findings into drug discovery and chemistry efforts. The company has advanced novel biology findings into proprietary small-molecule inhibitors and a growing pipeline of targeted therapies for genetically defined patient populations in liver, ovarian, colorectal, and breast cancers. Engine plans to expand its precision oncology portfolio, prepare for its first clinical programs, and scale its proprietary technology platform. Financially, the company recently closed a $43M Series A and has raised $53M to date, including a $10M seed round in 2018. Engine Biosciences is advancing a data-driven drug discovery platform that combines massively parallel biological experimentation with artificial intelligence to discover and develop therapies. The company applies its technology across four areas: drug repositioning, new target discovery, precision medicine enablement, and pathway analysis. Engine reports proof of concept across various disease indications and cell types and has active programs in cancer, neurodegeneration, autoimmune, and skin. The company plans to use the seed funding to build its drug discovery platform, expand its scientific and executive teams in Singapore and San Francisco, and pursue preclinical studies internally and with partners. Scientific leadership includes Co-Founder and CEO Jeffrey Lu and scientific founders/academic leaders Timothy Lu, Hu Li, Prashant Mali, and Jim Collins.

Total raised

$80M

Funding rounds

3

Latest round

Series A

Latest activity

Oct 2023